A SUB LINGUAL HYPO GLYCEMIC COMBINATION THAT HAS A FASTER ONSET, LONGER DURATION OF ACTION AND HIGHER EFFICACY AT OPTIMUM DOSAGE LEVEL COMPARED TO ALL PRESENTLY MARKETED ORAL HYPOGLYCEMIC DRUGS USED IN TYPE-II DIABETIS AND ASSOCIATED KETO ACIDOSIS AND LACTIC ACIDOSIS WORLD WIDE
The invention relates to a sublingual hypoglycemicombination that is far superior to those in current use in terms of onset time, duration and effectivity. Its efficacy increases on prolonged use requiring lowering in regimen. It is safer and less hepatotoxic. Its activity has been compared to drugs currently marketted and it has been found to be superior in the above mentioned as-pects. Moreover it may be used in diabetic coma, in lactic acidosis and diabetic keto acidosis associated with type II DM where other oral hypoglycemics are ineffective.
